Book a Meeting

Anti-EPCAM Antibody, Non-Fucosylated (BioBet-212ZP) (CAT#: BioBet-212ZP) Datasheet

Target
EPCAM
Isotype
IgG1
Description
ADCC-enhanced Tucotuzumab is a non-fucosylated anti-EPCAM therapeutic biobetter antibody.
Antibody Indication
Breast cancers
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EPCAM antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EPCAM
Full Name
Epithelial Cell Adhesion Molecule
Background
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]
Alternative Names
Adecatumumab; 503605-66-1; MT201; EPCAM; epithelial cell adhesion molecule; antigen identified by monoclonal AUA1, M4S1, MIC18, TACSTD1, tumor associated calcium signal transducer 1; 17 1A; 323/A3; CD326; CO 17A; EGP 2; EGP34; EGP40; Ep CAM; ESA; GA733 2; HEA125; KS1/4;
Gene ID
UniProt ID
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with EPCAM include Diarrhea 5, With Tufting Enteropathy, Congenital and Colorectal Cancer, Hereditary Nonpolyposis, Type 8.
Related Pathways
Its related pathways are Cell surface interactions at the vascular wall and Response to elevated platelet cytosolic Ca2+.
Function
It can be used as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and mucosal intraepithelial lymphocytes (IELs), providing an immune barrier, and acting as the first line of defense against mucosal infections. Play a role in the proliferation and differentiation of embryonic stem cells. Up-regulate the expression of FABP5, MYC and cyclins A and E.
Field of research
Controls and Markers antibody; Epithelial Marker antibody; Circulating Tumor Cells BioMarker antibody
Post-translational modifications
Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Tucotuzumab
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to EpCAM. Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).
Antibody Indication
Breast cancers

Breast cancers

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.